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6Objectives: The aim of the current Valve Academic Research Consortium (VARC)-2 initiativewas to revisit the
selection and definitions of transcatheter aortic valve implantation (TAVI) clinical endpoints to make themmore
suitable to the present and future needs of clinical trials. In addition, this document is intended to expand the
understanding of patient risk stratification and case selection.
Background: A recent study confirmed that VARC definitions have already been incorporated into clinical and
research practice and represent a new standard for consistency in reporting clinical outcomes of patients with
symptomatic severe aortic stenosis (AS) undergoing TAVI. However, as the clinical experience with this tech-
nology has matured and expanded, certain definitions have become unsuitable or ambiguous.
Methods andResults:Two in-personmeetings (held inSeptember2011 inWashington,DC,and inFebruary2012 in
Rotterdam, TheNetherlands) involvingVARC study groupmembers, independent experts (including surgeons, inter-
ventional and noninterventional cardiologists, imaging specialists, neurologists, geriatric specialists, and clinical tria-
lists), the US Food and Drug Administration (FDA), and industry representatives, provided much of the substantive
discussion from which this VARC-2 consensus manuscript was derived. This document provides an overview of
risk assessment and patient stratification that need to be considered for accurate patient inclusion in studies. Working
groups were assigned to define the following clinical endpoints: mortality, stroke, myocardial infarction, bleeding
complications, acute kidney injury, vascular complications, conduction disturbances and arrhythmias, and amiscella-
neous category including relevant complications not previously categorized. Furthermore, comprehensive echocardio-
graphic recommendations are provided for the evaluation of prosthetic valve (dys)function. Definitions for the quality
of life assessments are also reported. These endpoints formed the basis for several recommended composite endpoints.
Conclusions: ThisVARC-2 document has provided further standardization of endpoint definitions for studies eval-
uating the use ofTAVI,whichwill lead to improvedcomparability and interpretability of the study results, supplying
an increasingly growing body of evidence with respect to TAVI and/or surgical aortic valve replacement. This ini-
tiative and document can furthermore be used as a model during current endeavors of applying definitions to other
transcatheter valve therapies (for example, mitral valve repair). (J Thorac Cardiovasc Surg 2013;145:6-23)alve Academic Research Consortium (VARC) consists of representatives
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Kappetein et al Clinical GuidelinesINTRODUCTION
The first Valve Academic Research Consortium (VARC)
consensus manuscript was published in January 2011 with
the goal of achieving consensus for (i) selecting appropriate
clinical endpoints reflecting device, procedure and patient-
related effectiveness and safety, and (ii) standardizing defi-
nitions for single and composite clinical endpoints, for
transcatheter aortic valve implantation (TAVI) clinical tri-
als.1,2 A recent pooled analysis, which included 3519
patients from 16 unique studies, confirms that VARC
definitions have already been incorporated into clinical
and research practice and represent a new standard for
consistency in reporting clinical outcomes of patients with
symptomatic severe aortic stenosis (AS) undergoing
TAVI.3 However, as the clinical experience with this tech-
nology has matured and expanded, certain definitions
have become unsuitable or ambiguous.3-7 The aim of the
current VARC was therefore to revisit the selection and
definitions of TAVI-related clinical endpoints to make
them more suitable to the present and future needs of clin-
ical trials. In addition, this document is intended to expand
the understanding of patient risk stratification and case
selection.
Similar to the VARC-1 process, 2 in-person meetings
(held in September 2011 in Washington, DC, and in Febru-
ary 2012 in Rotterdam, The Netherlands) involving VARC
study group members, independent experts (including sur-
geons, interventional and noninterventional cardiologists,
imaging specialists, neurologists, geriatric specialists, and
clinical trialists), the US Food and Drug Administration
(FDA), and industry representatives, provided much of the
substantive discussion from which this VARC-2 consensus
manuscript was derived (see Appendices 1 and 2).RISK SCORES AND COMORBIDITIES
Risk stratification of patients is crucial to identifying ap-
propriate candidates for specific cardiac procedures. The
EuroSCORE and Society of Thoracic Surgeons (STS) score
are the most widely used risk scores to predict operative
mortality in cardiac surgery. These models were developed
and validated in a standard surgical risk population. The
predictive power of both models is therefore suboptimal
in high-risk patients with valvular disease, although the
STS score has shown to outperform the Logistic Euro-
SCORE.8 These models are even more limited in applica-
tion to patients who are considered at prohibitive risk for
cardiac surgery, a cohort that could particularly benefit
from TAVI. Current models could be improved by the addi-
tion of specific clinical and anatomical variables that affect
mortality.9 As an example, the presence of a porcelain aorta
and frailty are important factors not included in either risk
model but are routinely considered during patient evalua-
tion (Figure 1 and Table 1).The Journal of Thoracic andPerhaps the most important patient characteristic not in-
cluded in current risk models is frailty.10 Frailty is fre-
quently assessed subjectively based upon an informal
‘‘eyeball test’’. However, physical performance assess-
ments such as gait speed and grip strength are more objec-
tive performance measures that may capture an individual’s
overall functional status.11 These continuous measures are
reproducible and can be reassessed at various time points.
In addition, they require no language translation. Assess-
ments of cognition, weight (loss), activity level, and inde-
pendence in the activities of daily living provide
additional information on the overall health state of the in-
dividual.11 These limitations are more often found in pa-
tients with a high comorbidity burden and may coexist
with certain laboratory findings (eg, low serum albumin, el-
evated inflammatory markers, anemia) that further reflect
the health state and physiological reserve of the frail patient.
Baseline evaluation of the presence of cognitive dysfunc-
tion (mild cognitive impairment or dementia) has also
emerged as an essential part of the initial risk stratification,
especially in older populations, where the risk, benefit, and
cost-effectiveness of invasive procedures must be weighed
judiciously. Preprocedural cognitive assessment may also
help avoid attributing postprocedural mental status changes
to stroke categories. Among the several clinically estab-
lished rating scales (eg, Mini-Mental State Examination,
modified Telephone Interview of Cognitive Status
[TICS-M], Clinical Dementia Rating Scale),12 there is no
particular standard for TAVI. Nevertheless, some system-
atic cognitive assessment by neuropsychological experts
should be a part of the initial heart team evaluation.
Table 1 provides an overview of these and other risk fac-
tors (Figures 1-3) and VARC-2 recommendations on how
each should be assessed. In clinical trials, it will be impor-
tant to capture variables that predict extreme operative risk
and to standardize the evaluation criteria and process. This
will help to determine which subsets of patients are likely to
benefit from TAVI treatment.PATIENT STRATIFICATION: THE HEART TEAM
APPROACH
Valve Academic Research Consortium-2 recommends
the use of a heart team for patient evaluation. The heart
team should consist of at least (interventional) cardiolo-
gists, cardiovascular surgeons, and imaging specialists,
but its composition is dynamic and can also include
anesthesiologists, geriatricians, neurologists, etc. This
multi-disciplinary team should convene as a group on a reg-
ular basis to review and interpret clinical data to arrive at
a consensus on the optimal treatment strategy for each pa-
tient. The heart team approach also allows for the adjust-
ment of the decision-making process according to local
experience and circumstances.Cardiovascular Surgery c Volume 145, Number 1 7
FIGURE 1. Porcelain aorta or severely atherosclerotic aorta.
Clinical Guidelines Kappetein et alThe heart team should agree on an estimated 30-day mor-
tality risk for each patient based upon integrating a careful
clinical assessment and utilizing appropriate risk prediction
scoring systems, preferably the STS score. Surgical mortal-
ity risk strata are difficult to precisely assign, but an esti-
mated 30-day mortality of<4% is considered low risk,
4%-10% is intermediate risk, >10% is high risk, and
>15% is very high risk. A patient is considered at extreme
risk if at least 2 cardiovascular surgeons from a tertiary cen-
tre of excellence deny surgery because of prohibitive oper-
ative risks, estimated to be a combined >50% risk of
irreversible morbidity or mortality.13 In addition to the spe-
cific risk factors that can prohibit patients from undergoing
TAVI or surgical aortic valve replacement (SAVR) (Table
1), the operative risk assessment is also important to iden-
tify patients who are likely not to benefit from either
TAVI or SAVR (the so-called ‘‘futility’’ category of high-
risk patients). An expected improvement in the quality of
life (QOL) may further be necessary to identify treatment
responders versus non-responders. Individualized life ex-
pectancy assumptions should be incorporated by the heart
team in the clinical decision-making process as a central
factor in weighing the risk–benefit ratio. Prognostic indices
of life expectancy may play a central role in moving beyond
arbitrary age-based cut-offs.14
The most important role of the heart team is to provide
customizedmanagement decisions for common and unusual
clinical scenarios in terms of patient selection, procedural
performance, and complication management. An example
is the frequent situation of severe AS and concomitant cor-
onary artery disease (CAD). The complexity of CAD and
appropriate revascularization strategies in the setting of8 The Journal of Thoracic and Cardiovascular SurgerAS should be determined by consensus from interventional
cardiologists and cardiovascular surgeons.15,16 In new TAVI
clinical trials, angiographic risk scores (eg, SYNTAX score)
may be utilized to help determine the complexity of CAD, as
a basis for the inclusion in the trial. Thresholds for coronary
revascularization and the choice for a staged or concomitant
PCI with TAVI should be guided by the complexity of the
CAD and other factors as determined by the heart
team.17,18 In general, the plan to deal with other coexisting
conditions (such as atrial fibrillation [AF], other valvular
lesions, and other congenital lesions) should be
prespecified and all complications encountered in the
treatment of associated conditions (including treatment
after the TAVI procedure) should be captured. Such
thorough preprocedural assessment is also valuable in
discriminating new postprocedural complications from
simple exacerbations of pre-existing conditions.
CLINICAL ENDPOINTS
Mortality
In addition to the original VARC definitions, VARC-2
recommends the collection of immediate procedural mor-
tality to capture intra-procedural events that result in imme-
diate or consequent death72 h postprocedure. Taking into
account the surgical literature, procedural mortality con-
sists of all-cause mortality within 30 days or during index
procedure hospitalization—if the postoperative length of
stay is longer than 30 days.
The cause of death should be captured, based on a careful
review of narrative summaries and source material. All-
cause, cardiovascular, and noncardiovascular mortality
should be reported after 30 days during the follow-upy c January 2013
TABLE 1. Risk factors not captured by traditional risk scores
Comorbidities Definition/criteria Diagnostic modalities
Porcelain aorta or severely atherosclerotic aorta Heavy circumferential calcification or severe
atheromatous plaques of the entire ascending
aorta extending to the arch such that aortic
cross-clamping is not feasible
Noncontrast axial CT at levels:
Sinotubular junction
Tubular ascending aorta between the
sinotubular junction and the innominate
artery
Innominate artery
Entire transverse arch
Frailty Slowness, weakness, exhaustion, wasting and
malnutrition, poor endurance and inactivity,
loss of independence
Criteria:
5 m walking time*
Grip strength*
BMI<20 kg/m2 and/or weight loss 5 kg/year
Serum albumin<3.5 g/dL
Cognitive impairment or dementia
Medical history
Physical examination
Physical performance measures
Cognitive assessments
Laboratory tests
Severe liver disease/cirrhosis Any of the following:
Child-Pugh class C
MELD score 10
Portal-caval, spleno-renal, or transjugular
intrahepatic portal shunt
Biopsy proven cirrhosis with portal
hypertension or hepatocellular
dysfunction
Medical history
Physical examination
Laboratory tests
Child-Pugh classification
MELD score
Liver biopsy
Hostile chest Any of the following or other reasons that make
redo operation through sternotomy or right
anterior thoracotomyprohibitivelyhazardous:
Abnormal chest wall anatomy due to severe
kyphoscoliosis or other skeletal
abnormalities (including thoracoplasty,
Potts’ disease)
Complications from prior surgery
Evidence of severe radiation damage
(eg, skin burns, bone destruction, muscle
loss, lung fibrosis, or esophageal stricture)
History of multiple recurrent pleural
effusions causing internal adhesions
Medical history
Physical examination
Chest x-ray
CT scan
IMA or other critical conduit(s) crossing midline
and/or adherent to posterior table of sternum
A patent IMA graft that is adherent to the sternum
such that injuring it during reoperation is
likely.A patientmaybe considered at extreme
risk if any of the following are present:
The conduit(s) are radiographically
indistinguishable from the posterior table of
the sternum.
The conduit(s) are radiographically
distinguishable from the posterior table of
the sternum but lie within 2–3 mm of the
posterior table.
Axial CT scan images illustrating the graft
crossing the midline so that the distance from
sternum to graft can be measured.
Angiogram from the lateral and PA projections
and/or a CPR or VR (volume rendering) 3D
reconstructed CT scan image showing
relationships between the graft and the
sternum
Severe pulmonary hypertension
Severe right ventricular dysfunction
Primary or secondary pulmonary hypertension
with PA systolic pressures greater than two-
thirds of systemic pressure
Criteria as defined by the guidelines
(eg, TAPSE<15 mm, RVend-systolic area
>20 cm2, etc)y
Echocardiography, right and left-heart-
catheterization documenting PA and systemic
pressures
Documentation of secondary causes of
pulmonary hypertension
CT, Computed tomography; BMI, body mass index;MELD, Model for End-Stage Liver Disease; CPR, curved planar reformation; RV, right ventricular; IMA, internal mammary
artery; PA, pulmonary artery; TAPSE, tricuspid annular plane systolic excursion. *Variable with respect to age and gender without validated scientific thresholds. yRudski et al.71
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FIGURE 2. Hostile chest.
Clinical Guidelines Kappetein et al(Table 2). In determining the cause of death, the adjudica-
tion committee should consider the clinical context at the
time of the index procedure and during the time interval
leading up to death. All efforts (including the use of national
death registries) should be made to identify, precisely char-
acterize, and appropriately classify any death.
Myocardial Infarction
Myocardial injury as determined by a significant rise in
cardiac biomarkers occurs frequently following TAVI, and
a significant magnitude of myocardial injury has beenFIGURE 3. Patent IMA graft crossing midline an
10 The Journal of Thoracic and Cardiovascular Surgeassociated with worse outcomes.19 Valve Academic Re-
search Consortium-2 recommends the systematic collection
of biomarkers of myocardial injury prior to the procedure,
within 12-24 h after the procedure, at 24 h thereafter, at
72 h or at discharge, and, if still elevated, daily until values
show a decline. Similar to the previous VARC recommen-
dations, the definition of periprocedural (72 h following
TAVI) MI will be based on a combination of clinical criteria
and cardiac biomarkers. However, the threshold values have
been adjusted (Table 3). Acute ischemic events occurring
after 72 h should be considered spontaneous myocardial in-
farctions and defined in accordance with the universal MI
guidelines.20Stroke
With increasing attention to stroke as an important peri-
procedural complication of TAVI,21 the FDA has empha-
sized the need for an accurate assessment of stroke and
has participated actively in recommending specific details
of the VARC-2 definitions. In an attempt to further align
with the fundamental definitions now endorsed by the
FDA,22 consensus was reached at VARC-2 to further refine
the definition of stroke and recommend the use of these def-
initions in future TAVI clinical trials (Table 4). The defini-
tions endorsed by the FDA are intended to apply to a wide
range of clinical trials and to enable those trials to assess the
clinically relevant consequences of vascular brain injury for
determining the safety or effectiveness of an intervention.
Stroke is defined as an acute episode of focal or global
neurological dysfunction caused by the brain, spinal cord,
or retinal vascular injury as a result of hemorrhage ord/or adherent to the posterior table of sternum.
ry c January 2013
TABLE 2. Mortality
All-cause mortality
Cardiovascular mortality
Any of the following criteria
Death due to proximate cardiac cause (eg, myocardial infarction,
cardiac tamponade, worsening heart failure)
Death caused by noncoronary vascular conditions such as
neurological events, pulmonary embolism, ruptured aortic
aneurysm, dissecting aneurysm, or other vascular disease
All procedure-related deaths, including those related to
a complication of the procedure or treatment for a complication of
the procedure
All valve-related deaths including structural or nonstructural valve
dysfunction or other valve-related adverse events
Sudden or unwitnessed death
Death of unknown cause
Noncardiovascular mortality
Any death in which the primary cause of death is clearly related to
another condition (eg, trauma, cancer, suicide)
Kappetein et al Clinical Guidelinesinfarction. Stroke may be classified as ischemic or hemor-
rhagic with appropriate subdefinitions. Ischemic stroke is
defined as an acute episode of focal cerebral, spinal, or ret-
inal dysfunction caused by infarction of central nervous sys-
tem tissue. Hemorrhagic stroke is defined as an acute
episode of focal or global cerebral or spinal dysfunction
caused by intraparenchymal, intraventricular, or subarach-
noid hemorrhage. A stroke may be classified as ‘‘undeter-
mined’’ if there is insufficient information to allow the
categorization as ischemic or hemorrhagic.
An entity closely related to an ischemic stroke that should
be assessed is a transient ischemic attack (TIA). Transient
ischemic attack is defined as a transient episode of focal
neurological dysfunction caused by the brain, spinal cord,
or retinal ischemia, without acute infarction. The difference
between TIA and ischemic stroke is the presence of tissue
damage on neuro-imaging studies or new sensory–motor
deficit persisting>24 h. By definition, a TIA does not pro-
duce a lasting disability.
Valve Academic Research Consortium-2 recognizes that
an assessment of stroke is incomplete without an appropri-
ate measurement of the disability resulting from the stroke.
Valve Academic Research Consortium-2 recommends the
use of the modified Rankin Scale (mRS) to assess this clin-
ical disability.23-25 The assessment of the mRS should occur
at all scheduled visits in a trial and at 90 days after the onset
of any stroke. This approach will maximize the detection of
new or recurrent strokes, assist in the ongoing evaluation of
events previously determined as TIAs, and provide an
accepted and reliable indicator of the long-term impact of
a given stroke.
Previously, VARC recommended categorizing strokes as
‘‘major’’ and ‘‘minor’’ based upon mRS scores. To enhance
the accuracy in the description of a given stroke and to pro-
vide accurate categorization of strokes within a given trial,The Journal of Thoracic and CVARC-2 now recommends the use of the terms ‘‘disabling’’
and ‘‘nondisabling.’’ A disabling stroke is one that results
(at 90 days after stroke onset) in an mRS score of 2 and
an increase in 1 mRS category from an individual’s
prestroke baseline. A nondisabling stroke is one that results
(at 90 days after stroke onset) in an mRS score of<2 or that
does not result in an increase in 1 mRS category from an
individual’s prestroke baseline. In addition to this categori-
zation of disabling and nondisabling strokes, the endpoint
of all strokes should be reported.
Although brain imaging (typically, MRI for acute and
chronic ischemia and hemorrhage, and CT for acute and
chronic hemorrhage and chronic ischemia) is often used to
supplement the clinical diagnosis of stroke,26 a diagnosis
of stroke may be made on clinical grounds alone. Valve Ac-
ademicResearchConsortium-2 recognizes that stroke symp-
toms are protean and not well suited to a prespecified
itemized listing. Accordingly, VARC-2 recommends that
a vascular neurologist experienced in clinical trials involving
stroke be included in all phases of trial planning, execution,
andmonitoring, including involvement in theClinical Events
Committee and the Data and Safety Monitoring Board.
New insights into the timing of events show delayed or
late occurrence of strokes, beyond the early postimplanta-
tion phase.27 This may suggest that the cause of stroke is ad-
ditionally related to other factors or patient susceptibilities
and should necessitate active investigation of devices and
adjunctive pharmacotherapy to reduce the frequency and
severity of strokes after TAVI, including precise documen-
tation of the use and dosage of antithrombotic and antipla-
telet medication. Patient baseline characteristics (eg,
carotid stenosis) and postoperative complications (eg, AF)
need to be carefully documented to be able to identify the
contributing causes of stroke.
Invasive stroke management (catheter-based intracranial
intervention) is gaining an increasingly important role and
may impact morbidity and mortality. Valve Academic Re-
search Consortium-2 therefore recommends the ascertain-
ment of any acute stroke management strategy (eg,
aspiration, thrombolysis, or conservative management).
Bleeding Complications
Valve Academic Research Consortium-2 acknowledges
the fact that the Bleeding Academic Research Consortium
(BARC) recently convened and established standardized
bleeding definitions for patients receiving antithrombotic
therapy and undergoing coronary revascularization (PCI
or CABG).28,29 However, because the current definitions
have been well adopted and shown to be accurate in
predicting adverse events,30 VARC-2 has chosen to main-
tain the original VARC definitions with BARC classifica-
tions (Table 5), recognizing that future validation of
BARC criteria in this population may warrant revision of
the current recommendations.ardiovascular Surgery c Volume 145, Number 1 11
TABLE 3. Myocardial infarction
Periprocedural MI (72 h after the index procedure)
New ischemic symptoms (eg, chest pain or shortness of breath), or new
ischemic signs (eg, ventricular arrhythmias, new or worsening heart
failure, new ST-segment changes, hemodynamic instability, new
pathological Q-waves in at least 2 contiguous leads, imaging
evidence of new loss of viable myocardium or new wall motion
abnormality) AND
Elevated cardiac biomarkers (preferable CK-MB) within 72 h after the
index procedure, consisting of at least 1 sample postprocedure with
a peak value exceeding 153 as the upper reference limit for troponin
or 53 for CK-MB.* If cardiac biomarkers are increased at baseline
(>99th percentile), a further increase in at least 50% postprocedure is
required AND the peak value must exceed the previously stated limit
Spontaneous MI (>72 h after the index procedure)
Any 1 of the following criteria:
Detection of rise and/or fall of cardiac biomarkers (preferably troponin)
with at least 1 value above the 99th percentile URL, together with
the evidence of myocardial ischemia with at least 1 of the
following:
Symptoms of ischemia
ECG changes indicative of new ischemia [new ST-T changes or
new left bundle branch block (LBBB)]
New pathological Q-waves in at least 2 contiguous leads
Imaging evidence of a new loss of viable myocardium or new wall
motion abnormality
Sudden, unexpected cardiac death, involving cardiac arrest, often with
symptoms suggestive of myocardial ischemia, and accompanied by
presumably new ST elevation, or new LBBB, and/or evidence of
fresh thrombus by coronary angiography and/or at autopsy, but death
occurring before blood samples could be obtained, or at a time
before the appearance of cardiac biomarkers in the blood.
Pathological findings of an acute myocardial infarction
*Previously in the original VARC it was 103 and 53 for troponin and CK-MB,
respectively.
TABLE 4. Stroke and TIA
Diagnostic criteria
Acute episode of a focal or global neurological deficit with at least 1 of
the following: change in the level of consciousness, hemiplegia,
hemiparesis, numbness, or sensory loss affecting 1 side of the body,
dysphasia or aphasia, hemianopia, amaurosis fugax, or other
neurological signs or symptoms consistent with stroke
Stroke: duration of a focal or global neurological deficit24 h; OR<24
h if available neuroimaging documents a new hemorrhage or infarct;
OR the neurological deficit results in death
TIA: duration of a focal or global neurological deficit<24 h, any
variable neuroimaging does not demonstrate a new hemorrhage or
infarct
No other readily identifiable nonstroke cause for the clinical
presentation (eg, brain tumor, trauma, infection, hypoglycemia,
peripheral lesion, pharmacological influences), to be determined by
or in conjunction with the designated neurologist*
Confirmation of the diagnosis by at least 1 of the following:
Neurologist or neurosurgical specialist
Neuroimaging procedure (CT scan or brain MRI), but stroke may be
diagnosed on clinical grounds alone
Stroke classification
Ischemic: an acute episode of focal cerebral, spinal, or retinal
dysfunction caused by infarction of the central nervous system tissue
Hemorrhagic: an acute episode of focal or global cerebral or spinal
dysfunction caused by intraparenchymal, intraventricular, or
subarachnoid hemorrhage
A stroke may be classified as undetermined if there is insufficient
information to allow categorization as ischemic or hemorrhagic
Stroke definitionsy
Disabling stroke: an mRS score of 2 or more at 90 days and an increase
in at least 1 mRS category from an individual’s prestroke baseline
Nondisabling stroke: an mRS score of<2 at 90 days or one that does
not result in an increase in at least 1 mRS category from an
individual’s prestroke baseline
mRS, Modified Rankin Scale. *Patients with nonfocal global encephalopathy will not
be reported as a stroke without unequivocal evidence of cerebral infarction-based
upon neuroimaging studies (CT scan or Brain MRI). yModified Rankin Scale
assessments should be made by qualified individuals according to a certification
process.23-25
Clinical Guidelines Kappetein et alWith respect to blood transfusions, it is critical to ac-
knowledge that a bleeding complication has to be the result
of overt bleeding and cannot be adjudicated based on blood
transfusions alone.
Acute Kidney Injury
The original VARC definitions recommended the use of
a modified version of the RIFLE classification. However,
we now recommend using the AKIN system (Table 6), which
is amodified versionofRIFLE that has been adoptedbymany
in the nephrology community, including the KDIGO initia-
tive.31,32 As a result, acute kidney injury (AKI) can also be
diagnosed according to urine output measures (Table 6).
In comparison with the original VARC, the timing for the
diagnosis of AKI is extended from 72 h to 7 days. Patients
who experience AKI should have follow-up renal function
assessments after 7 days until stabilization.Vascular Complications
Table 7 lists VARC-2 definitions for major and minor
vascular complications. Further clarifications of these12 The Journal of Thoracic and Cardiovascular Surgedefinitions to supplement the original VARC document
are as follows. Preplanned surgical access or a planned en-
dovascular approach to vascular closure (eg, ‘‘preclo-
sure’’)33,34 should be considered as part of the TAVI
procedure and not as a complication, unless untoward
clinical consequences are documented (eg, bleeding
complications, limb ischemia, distal embolization, or
neurological impairment). Unplanned endovascular
stenting or surgical repair for any vascular complications
during the index procedure without other clinical sequelae
should be considered a minor vascular complication,
except if associated with qualifying consequences
(Table 7). Complications related to alternative access sites,
including the left-ventricular apex, subclavian artery, or
aorta should be systematically recorded. To ensure accuratery c January 2013
TABLE 5. Bleeding
Life-threatening or disabling bleeding
Fatal bleeding (BARC type 5) OR
Bleeding in a critical organ, such as intracranial, intraspinal,
intraocular, or pericardial necessitating pericardiocentesis, or
intramuscular with compartment syndrome (BARC type 3b and 3c)
OR
Bleeding causing hypovolemic shock or severe hypotension requiring
vasopressors or surgery (BARC type 3b) OR
Overt source of bleeding with drop in hemoglobin 5 g/dL or whole
blood or packed red blood cells (RBCs) transfusion 4 units*
(BARC type 3b)
Major bleeding (BARC type 3a)
Overt bleeding either associated with a drop in the hemoglobin level of
at least 3.0 g/dL or requiring transfusion of 2 or 3 units of whole
blood/RBC, or causing hospitalization or permanent injury, or
requiring surgery AND
Does not meet criteria of life-threatening or disabling bleeding
Minor bleeding (BARC type 2 or 3a, depending on the severity)
Any bleeding worthy of clinical mention (eg, access site hematoma)
that does not qualify as life-threatening, disabling, or major
BARC, Bleeding Academic Research Consortium29; RBC, red blood cell. *Given that
1 unit of packed RBC typically will raise the hemoglobin concentration by 1 g/dL, an
estimated decrease in hemoglobin will be calculated.
TABLE 7. Vascular access site and access-related complications
Major vascular complications
Any aortic dissection, aortic rupture, annulus rupture, left ventricle
perforation, or new apical aneurysm/pseudoaneurysm OR
Access site or access-related vascular injury (dissection, stenosis,
perforation, rupture, arterio-venous fistula, pseudoaneurysm,
hematoma, irreversible nerve injury, compartment syndrome,
percutaneous closure device failure) leading to death, life-
threatening or major bleeding,* visceral ischemia, or neurological
impairment OR
Distal embolization (noncerebral) from a vascular source requiring
surgery or resulting in amputation or irreversible end-organ damage
OR
The use of unplanned endovascular or surgical intervention associated
with death, major bleeding, visceral ischemia or neurological
impairment OR
Any new ipsilateral lower extremity ischemia documented by patient
symptoms, physical exam, and/or decreased or absent blood flow on
lower extremity angiogram OR
Surgery for access site-related nerve injury OR
Permanent access site-related nerve injury
Minor vascular complications
Access site or access-related vascular injury (dissection, stenosis,
perforation, rupture, arterio-venous fistula, pseudoaneuysms,
hematomas, percutaneous closure device failure) not leading to
death, life-threatening or major bleeding,* visceral ischemia, or
neurological impairment OR
Distal embolization treated with embolectomy and/or thrombectomy
and not resulting in amputation or irreversible end-organ damage
OR
Any unplanned endovascular stenting or unplanned surgical
intervention not meeting the criteria for a major vascular
complication OR
Vascular repair or the need for vascular repair (via surgery, ultrasound-
guided compression, transcatheter embolization, or stent-graft)
Percutaneous closure device failure
Failure of a closure device to achieve hemostasis at the arteriotomy site
leading to alternative treatment (other than manual compression or
adjunctive endovascular ballooning)
Kappetein et al Clinical Guidelinescapture of these elements, VARC-2 strongly recommends
that detailed information regarding the access site and
preplanned vascular closure technique be recorded as well
as the use of any additional unplanned access or closure
techniques (surgical repair, endovascular stenting, or endo-
vascular balloon therapy). Since many vascular complica-
tions will also result in a bleeding complication, events
that meet VARC-2 definitions for both categories should
be reported in both categories. Finally, VARC-2 recom-
mends that all vascular complications be recorded as either
access (eg, iliac rupture) or nonaccess site-related (eg, as-
cending aorta dissection or rupture unless aortic access is
used and the event originates from the cannulation site).TABLE 6. Acute kidney injury (AKIN classification*)
Stage 1
Increase in serum creatinine to 150%-199% (1.5-1.99 3 increase
compared with baseline) OR increase of 0.3 mg/dL (26.4
mmol/L) OR
Urine output<0.5 mL/kg/h for>6 but<12 h
Stage 2
Increase in serum creatinine to 200%-299% (2.0%-2.99% increase
compared with baseline) OR
Urine output<0.5 mL/kg/h for>12 but<24 h
Stage 3y
Increase in serum creatinine to300% (>33 increase compared with
baseline) OR serum creatinine of 4.0 mg/dL (354 mmol/L) with
an acute increase of at least 0.5 mg/dL (44 mmol/L) OR
Urine output<0.3 ml/kg/h for 24 h OR
Anuria for 12 h
The increase in creatinine must occur within 48 h. *Mehta et al.31 yPatients receiving
renal replacement therapy are considered to meet Stage 3 criteria irrespective of other
criteria.
*Refers to VARC bleeding definitions.
The Journal of Thoracic and CConduction Disturbances and Arrhythmias
Valve Academic Research Consortium-2 proposes
the systematic collection of data on the frequency of
implant-related new and/or worsened conduction distur-
bances and the incidence and indication for permanent
pacemaker implantation (Table 8). In addition, the fre-
quency of specific arrhythmias following TAVI should be
recorded as they may result in prolonged hospitalization
and impaired clinical outcomes. New-onset AF (or flutter)
is diagnosed as any arrhythmia within hospitalization that
has the ECG characteristics of AF and lasts sufficiently
long to be recorded on a 12-lead ECG, or for at least 30 s
on a rhythm strip.35 The therapeutic approach to new-
onset AF (spontaneous conversion, electrical or medical
cardioversion, initiation of oral anticoagulation, and rate
or rhythm control medications) and any clinicalardiovascular Surgery c Volume 145, Number 1 13
TABLE 8. Conduction disturbances and arrhythmias
Up to 72 h, continuous rhythm monitoring is recommended in order to
maximize the detection of arrhythmias
Data elements to be collected should include
Baseline conduction abnormalities, paroxysmal or permanent atrial
fibrillation (or flutter), and the presence of permanent pacemaker*
Implant-related new or worsened cardiac conduction disturbance (new
or worsened first-degree atrioventricular (AV) block, second-degree
AV block (Mobitz I orMobitz II), third-degree AV block, incomplete
right bundle branch block, right bundle branch block,
intraventricular conduction delay, left bundle branch block, left
anterior fascicular block, or left posterior fascicular block, including
block requiring a permanent pacemaker implant
Persistent or transient high-degree AV block. High-grade AV block is
persistent if it is present every time the underlying rhythm is checked
New permanent pacemaker implantation, with precision of the
indication and the number of days postimplant of the placement of
new permanent pacemaker
New-onset atrial fibrillation (or flutter)y
Any new arrhythmia resulting in hemodynamic instability or requiring
therapyz
*Type of permanent pacemaker should be recorded (eg, defibrillator, single vs dual
chamber, biventricular). yNew-onset atrial fibrillation (or flutter) is diagnosed as
any arrhythmia within hospitalization that has the ECG characteristics of atrial fibril-
lation (or flutter) and lasts sufficiently long to be recorded on a 12-lead ECG, or at
least 30 s on a rhythm strip. zTherapy includes electrical/medical cardioversion or ini-
tiation of a newmedication (oral anticoagulation, rhythm, or rate controlling therapy).
TABLE 9. Other TAVI-related complications
Conversion to open surgery
Conversion to open sternotomy during the TAVI procedure secondary
to any procedure-related complications
Unplanned use of cardiopulmonary bypass (CPB)
Unplanned use of CPB for hemodynamic support at any time during the
TAVI procedure
Coronary obstruction
Angiographic or echocardiographic evidence of a new, partial or
complete, obstruction of a coronary ostium, either by the valve
prosthesis itself, the native leaflets, calcifications, or dissection,
occurring during or after the TAVI procedure
Ventricular septal perforation
Angiographic or echocardiographic evidence of a new septal
perforation during or after the TAVI procedure
Mitral valve apparatus damage or dysfunction
Angiographic or echocardiographic evidence of new damage (chordae
papillary muscle, or to the leaflet) to the mitral valve apparatus or
dysfunction (eg, restrictions due to the THV) of the mitral valve
during or after the TAVI procedure
Cardiac tamponade
Evidence of a new pericardial effusion associated with hemodynamic
instability and clearly related to the TAVI procedure
Endocarditis
Any 1 of the following:
Fulfilment of the Duke endocarditis criteria*
Evidence of abscess, paravalvular leak, pus, or vegetation confirmed as
secondary to infection by histological or bacteriological studies
during a reoperation
Findings of abscess, pus, or vegetation involving a repaired or replaced
valve during an autopsy
Valve thrombosis
Any thrombus attached to or near an implanted valve that occludes part
of the blood flow path, interferes with valve function, or is
sufficiently large to warrant treatment. Note that valve-associated
thrombus identified at autopsy in a patient whose cause of death was
not valve-related should not be reported as valve thrombosis
Valve malpositioning
Valve migration
After initial correct positioning, the valve prosthesis moves upwards
or downwards, within the aortic annulus from its initial position,
with or without consequences
Valve embolization
The valve prosthesis moves during or after deployment such that it
loses contact with the aortic annulus
Ectopic valve deployment
Permanent deployment of the valve prosthesis in a location other
than the aortic root
TAV-in-TAV deployment
An additional valve prosthesis is implanted within a previously
implanted prosthesis because of suboptimal device position and/or
function, during or after the index procedure
TAVI, Transcatheter aortic valve implantation; THV, transcatheter heart valve.
*Durack et al.72
Clinical Guidelines Kappetein et alconsequences should be thoroughly documented in the case
report form.
Other TAVI-Related Complications
The original VARC document recommended the collec-
tion of a number of TAVI-related complications, but did
not provide specific endpoint definitions for several end-
points. Valve Academic Research Consortium-2 recom-
mends reporting any other complications related to the
TAVI procedure, even those occurring less frequently, and
provides formal VARC-2 definitions (Table 9).36-38
Additional Considerations
For studies or trials where the occurrence, prevention, or
treatment of cerebral infarction is a fundamental feature
(eg, embolic protection devices) additional appropriate im-
aging in all or a subset of patients may be necessary to allow
determination of effectiveness.
VALVULAR FUNCTION
Valve Academic Research Consortium-2 maintains the
original recommendations to use echocardiography as the
primary imaging modality for the assessment of prosthetic
valve function.39 This should include the valve position,
morphology, function, and evaluation of the left ventricle
(LV) and right ventricle (RV) size and function. The sug-
gested time points for routine follow-up transthoracic echo-
cardiography (TTE) following valve implantation are:14 The Journal of Thoracic and Cardiovascular Surgeimmediately (before discharge) following the implantation
for transarterial approaches or within 30 days for transapi-
cal or transaortic approaches, 6 months followingry c January 2013
TABLE 10. Prosthetic valve dysfunction
Prosthetic aortic valve stenosis*
Normal Mild stenosis Moderate/severe stenosis
Quantitative parameters (flow-dependent)y
Peak velocity (m/s) <3 m/s 3-4 m/s >4 m/s
Mean gradient (mm Hg) <20 mm Hg 20-40 mm Hg >40 mm Hg
Quantitative parameters (flow-independent)
Doppler velocity indexz >0.35 0.35-0.25 <0.25
Effective orifice areax >1.1 cm2 1.1-0.8 cm2 <0.8 cm2
Effective orifice areak >0.9 cm2 0.9-0.6 cm2 <0.6 cm2
Prosthesis–patient mismatch (PPM)
Insignificant Moderate Severe
Indexed effective orifice area{ (cm2/m2) >0.85 cm2/m2 0.85-0.65 cm2/m2 <0.65 cm2/m2
Indexed effective orifice area# (cm2/m2) >0.70 cm2/m2 0.90-0.60 cm2/m2 <0.60 cm2/m2
Prosthetic aortic valve regurgitation
Mild Moderate Severe
Semiquantitative parameters
Diastolic flow reversal in the descending aorta—PW Absent or brief early diastolic Intermediate Prominent, holodiastolic
Circumferential extent of prosthetic valve paravalvular
regurgitation (%)**
<10% 10%-29% 30%
Quantitative parametersz
Regurgitant volume (mL/beat) <30 mL 30-59 mL 60 mL
Regurgitant fraction (%) <30% 30-49% 50%
EROA (cm2) 0.10 cm2 0.10-0.29 cm2 0.30 cm2
PW, Pulsed wave; EROA, effective regurgitant orifice area. *In conditions of normal or near normal stroke volume (50-70 mL). yThese parameters are more affected by flow,
including concomitant aortic regurgitation. zFor LVOT>2.5 cm, significant stenosis criteria is<0.20. xUse in setting of BSA 1.6 cm2 (note: dependent on the size of the valve
and the size of the native annulus). kUse in setting of BSA<1.6 cm2. {Use in setting of BMI<30 kg/cm2. #Use in setting of BMI 30 kg/cm2. **Not well-validated and may
overestimate the severity compared with the quantitative Doppler.
Kappetein et al Clinical Guidelinesimplantation, 1 year following implantation, and yearly
thereafter. At these endpoints, prosthetic aortic valve steno-
sis and regurgitation should be reported.
Transcatheter Valve Stenosis
The assessment of prosthetic valve stenosis should be an
integrative process utilizing multiple parameters of valve
function. Table 10 outlines the primary parameters used
for assessing prosthetic valve function based on published
guidelines.40 Divergence from the guidelines is based on
a number of studies,41,42 as well as methods used in large
randomized control trials of TAVI.43,44 In addition,
VARC-2 does not recommend using acceleration time,
which is dependent on ventricular function and heart
rate.42 The limitation of flow-dependent parameters such
as peak jet velocity or mean transprosthetic gradient is ob-
vious, however, even flow-independent parameters such as
the effective orifice area (EOA) and the Doppler velocity in-
dex (DVI) have limitations: (i) the absolute EOA does not
account for the cardiac output requirements in relation to
the patient’s body size; thus lower criteria should be used
to define prosthetic valve stenosis in patients with BSA
<1.6 m2 (Table 10), (ii) the indexed EOA may overestimateThe Journal of Thoracic and Cthe valve-related hemodynamic burden in obesity; hence,
lower criteria may be more appropriate in patients with
a body mass index 30 kg/m2, (iii) DVI severity criteria
are dependent on the left ventricular outflow tract (LVOT)
size; thus a lower threshold may be more appropriate in pa-
tients with LVOT diameters of>25 mm. The EOA should
generally be calculated with the use of the LVOT diameter
and the velocity measured just underneath the apical margin
of the valve stent.45,46 In cases where the landing zone of the
stent is low in the LVOT, the diameter and velocity may both
be measured in the proximal portion of the stent. Unlike the
surgically implanted valve, the transcatheter prosthetic
valve EOA is defined not only by the size of the valve but
also by the patient’s aortic valve/annular anatomy and
procedural variables. Thus, well-established normal trans-
catheter valve gradients and EOAs based on preimplant aor-
tic annular dimensions do not currently exist. Clinicians
should be aware of this variability when assessing a patient
for transcatheter valve function and VARC-2 strongly rec-
ommends that the patient’s own initial postimplant study
be used as a reference for serial comparisons.
The assessment of transcatheter valve dysfunction in-
cludes the immediate post-TAVI hemodynamics and theardiovascular Surgery c Volume 145, Number 1 15
FIGURE 4. Transcatheter heart valve hemodynamic evaluation algorithm.
Clinical Guidelines Kappetein et alfollow-up evaluation. The immediate post-TAVI evalua-
tion documents initial valve appearance (position and cir-
cularity of the stent, and leaflet morphology and motion)
and a comprehensive hemodynamic evaluation. Valve Ac-
ademic Research Consortium-2 advocates using the inte-
grative approach outlined in the algorithm shown in
Figure 4 as part of a comprehensive hemodynamic evalu-
ation by using 1 flow dependent (eg, mean gradient) and 1
flow independent criterion (eg, EOA) for the initial hemo-
dynamic evaluation. If there is discordance between these
measurements, then the DVI should be calculated. An ab-
normal DVI indicates possible prosthetic valve dysfunc-
tion. A normal DVI indicates intrinsically normal
prosthetic valve function, and the indexed EOA can then
be used to determine the reason for the initial measure-
ment discordance. When the indexed EOA is low in the
setting of a normal DVI, the patient probably has a prosthe-
sis–patient mismatch (PPM), an indicator of the intrinsic
relationship of the implanted valve to the cardiac output
requirements of the patient.47 Prosthesis–patient mismatch
occurs in the setting of a morphologically normal valve
and is considered to be hemodynamically insignificant if
the indexed EOA is>0.85 cm2/m2, moderate if between16 The Journal of Thoracic and Cardiovascular Surge0.65 and 0.85 cm2/m2, and severe if<0.65 cm2/m2. How-
ever, for obese patients (body mass index 30 kg/m2)
lower criteria may be more appropriate (Table 10).
Transcatheter Valve Regurgitation
There is growing evidence suggesting a significant asso-
ciation of postprocedural paravalvular aortic regurgitation
(AR) with short- and long-term mortality.48,49 As the
duration of implanted transcatheter heart valves increases,
valve durability and dysfunction become more crucial
issues. Evaluating the presence and severity of
regurgitation should include an assessment of both
central and paravalvular components, with a combined
measurement of ‘‘total’’ aortic regurgitation (AR)
reflecting the total volume load imposed on the LV (Table
10). The quantitative and semiquantitative hemodynamic
assessment of AR severity should be performed with Dopp-
ler echocardiography according to the guidelines.39,50,51
Color Doppler evaluation should be performed just below
the valve stent for paravalvular jets, and at the coaptation
point of the leaflets for central regurgitation. Although
all imaging windows should be used, the parasternal
short-axis view is critical in assessing the number andry c January 2013
Kappetein et al Clinical Guidelinesseverity of paravalvular jets. Whenever possible, the
quantification of the prosthetic regurgitant volume, effec-
tive regurgitant orifice area, and regurgitant fraction
(Table 10) should be performed.40,51,52 The regurgitant
volume may be calculated as the difference between the
stroke volume across any nonregurgitant orifice (RVOT or
mitral valve) and the stroke volume across the LVOT.
It is important to realize that at this time the body of ev-
idence supporting the numerical criteria used in Table 10 as
well as Figure 4 may be limited. These criteria should be
used as guidelines for clinical decision-making and require
further validation as our experience continues to expand.
Follow-up Assessments
The follow-up assessment should also begin with valve
imaging and documentation of changes in morphology.
When determining whether a patient has developed hemo-
dynamically significant structural valve failure, the pa-
tient’s own baseline echocardiographic parameters should
be used as a reference. An increase in the mean gradient
>10 mm Hg, a decrease in the EOA>0.3-0.4 cm2, or a re-
duction in the DVI>0.1-0.13 probably indicates a change in
valve function and should trigger a comprehensive hemody-
namic evaluation. Whenever valve dysfunction is sus-
pected, the careful evaluation of valve morphology should
confirm a structurally abnormal valve. In addition, measure-
ment error must be excluded; the use of a consistent LVOT
diameter for more accurate follow-up study comparisons is
recommended. Finally, changes in ventricular morphology
would be expected in the setting of long-standing signifi-
cant valvular dysfunction and this parameter may support
the clinical assessment of severity.
Although the rate of moderate or severe regurgitation
may appear to be less at the follow-up, this may be the result
of attrition of the sickest patients. To assess such time
trends, it is recommended to report an individual patient’s
progression of regurgitation, in a table that provides
changes between short-term and long-term regurgitation,
including mortality.48
QUALITY OF LIFE
Quality of Life Evaluation in Aortic Stenosis
New York Heart Association (NYHA) classification is
limited by the discrete nature of the scale, which provides
only modest resolution to detect clinically relevant changes.
Moreover, since the NYHA class is assessed by an external
body rather than the patient, it does not reflect the patient’s
perspective. Thus, the NYHA class is more properly consid-
ered a measure of the functional status than the QOL.
The Minnesota Living with Heart Failure Questionnaire
(MLHF)53 and the Kansas City Cardiomyopathy Question-
naire (KCCQ)54,55 have a number of desirable properties for
the evaluation of health-related QOL (HRQOL) in the set-
ting of AS. Both instruments produce outcomes onThe Journal of Thoracic and Ca continuous scale, which improves responsiveness and sen-
sitivity. Although only the MLHF has been specifically val-
idated in patients with aortic valve disease,56 preliminary
experience with the KCCQ in patients undergoing TAVI
has also demonstrated a high degree of responsiveness
and internal consistency.57
Recommended Endpoints and Timing of Assessment
Valve Academic Research Consortium-2 recommends
that a comprehensive assessment of HRQOL for patients
undergoing TAVI incorporate both a heart failure-specific
measure (such as the KCCQ or MLHF) as well as 1 or
more generic measures (such as the Medical Outcomes
Study Short-Form 36 [SF-36], the Short-Form 12 [SF-12],
or the EuroQOL [EQ-5D]).58-60 The disease-specific mea-
sures offer improved sensitivity/responsiveness as well as
clinical interpretability, whereas the inclusion of a generic
health status measure is useful because it captures some ad-
ditional domains. Furthermore, generic measures can en-
hance the comparability across different diseases and
populations and can be used to compare patients with
population-level benchmarks.
For the comparison of TAVI versus SAVR (or for the
comparison of alternative access sites for TAVI), we recom-
mend that early QOL assessment be performed at 2 weeks, 1
month, and 3 months using a combination of generic instru-
ments and pain scales (eg, visual analogue scale) to assess
the early recovery process. The evaluation of the QOL at
an intermediate time point (eg, 6 months) could also be con-
sidered in order to confirm that QOL recovery is complete
by this stage. At later time points (1-5 years), the use of
heart failure-specific instruments to identify the conse-
quences of long-term valve performance may be more use-
ful. Finally, the assessment of cognitive function at later
time points (1-5 years) may be valuable for the comparison
of surgical versus catheter-based techniques, although these
endpoints generally require highly specialized and demand-
ing neuropsychiatric testing.61 In contrast, for the compari-
son of alternative TAVI systems (as may be expected in the
near future), HRQOL assessment should focus mainly on
heart failure-specific endpoints at intermediate and later
time points (1-5 years), wherein between-device differences
in the hemodynamic performance or structural valve deteri-
oration may emerge. The inclusion of disease-specific QOL
measures in these studies can also provide insight into the
consequences of valve-related complications such as the
need for pacemaker insertion.
Additional Considerations
It is essential to ensure complete ascertainment of
HRQOL at each time point, as missing data cannot be re-
trieved retrospectively and statistical adjustment techniques
(eg, multiple imputation) that assume that data are ‘‘missing
at random’’ may not be adequate. Differential mortalityardiovascular Surgery c Volume 145, Number 1 17
TABLE 11. Composite endpoints
Device success
Absence of procedural mortality AND
Correct positioning of a single prosthetic heart valve into the proper
anatomical location AND
Intended performance of the prosthetic heart valve (no prosthesis–
patient mismatch* and mean aortic valve gradient<20 mm Hg or
peak velocity<3 m/s, AND no moderate or severe prosthetic valve
regurgitation*)
Early safety (at 30 days)
All-cause mortality
All stroke (disabling and nondisabling)
Life-threatening bleeding
Acute kidney injury—Stage 2 or 3 (including renal replacement
therapy)
Coronary artery obstruction requiring intervention
Major vascular complication
Valve-related dysfunction requiring repeat procedure (BAV, TAVI, or
SAVR)
Clinical efficacy (after 30 days)
All-cause mortality
All stroke (disabling and nondisabling)
Requiring hospitalizations for valve-related symptoms or worsening
congestive heart failurey
NYHA class III or IV
Valve-related dysfunction (mean aortic valve gradient 20 mm Hg,
EOA 0.9–1.1 cm2z and/or DVI<0. 35 m/s, AND/OR moderate or
severe prosthetic valve regurgitation*)
Time-related valve safety
Structural valve deterioration
Valve-related dysfunction (mean aortic valve gradient 20 mm Hg,
EOA 0.9-1.1 cm2z and/or DVI<0.35 m/s, AND/OR moderate
or severe prosthetic valve regurgitation*)
Requiring repeat procedure (TAVI or SAVR)
Prosthetic valve endocarditis
Prosthetic valve thrombosis
Thrombo-embolic events (eg, stroke)
VARC bleeding, unless clearly unrelated to valve therapy (eg, trauma)
BAV, Balloon aortic valvuloplasty; TAVI, transcatheter aortic valve implantation;
SAVR, surgical aortic valve replacement. *Refers to VARC definitions. yAs a basis
for calculation of ‘‘days alive outside the hospital’’ endpoint. Supplementary appen-
dix of Leon et al.43 Includes heart failure, angina, or syncope due to aortic valve dis-
ease requiring intervention or intensified medical management; clinical symptoms of
CHF with objective signs including pulmonary edema, hypoperfusion, or docu-
mented volume overload AND administration of IV diuresis or inotropic therapy, per-
formance of aortic valvuloplasty, institution of mechanical support (IABP or
ventilation for pulmonary edema) or hemodialysis for volume overload; clear docu-
mentation of anginal symptoms AND no clinical evidence that angina was related to
CAD or ACS; documented loss of consciousness not related to seizure or tachyar-
rhythmia. zDepending on the body surface area.
Clinical Guidelines Kappetein et albetween 2 treatments may complicate the interpretation of
QOL results since the QOL may appear to ‘‘improve’’
over time even with an ineffective therapy simply because
of attrition of the sickest patients. The use of categorical
endpoints that characterize outcomes as favorable (eg, sur-
vival AND improvement of QOL endpoints)44,57 or
endpoints that integrate survival and the QOL (eg,
quality-adjusted life expectancy) may provide more inter-
pretable results. In such cases, reporting the outcomes in
both ways (ie, among the entire study cohort and separately
among only the surviving patients) will provide the most
complete description of the results.
COMPOSITE ENDPOINTS
Rationale and Caveats
Comparisons of the success, safety, and effectivenesswith
achievable study cohort sample sizes may at times require
the use of composite endpoints. However, it is important
that composites contain components that have roughly sim-
ilar impacts on the patient. A family of single endpoints
tending in the same directionmay, as a family of hypotheses,
be statistically significantwhen individual endpoints are not.
Each postprocedural event has a different temporal risk
profile (hazard function) modulated by different risk fac-
tors. Therefore, traditionally, the evaluation of the safety
and efficacy of procedures has focused on in-hospital events
(complications and morbidity), events within 30 days of the
procedure, and ‘‘late’’ events.
Specific Composite Endpoints
The assessment of TAVI, SAVR, and their alternatives or
new devices should include device, procedure, and patient-
oriented endpoints. These endpoints have been devised to
be applicable to both TAVI and SAVR. Previous clinical tri-
als have used the all-cause mortality at 1 year as the primary
clinical endpoint. Owing to the emergence of stroke as an
important clinical event, future trials should also require
the composite of all-cause mortality and disabling stroke
as a primary or secondary endpoint.
The first VARC document proposed 3 composite end-
points: device success, early safety, and clinical efficacy.
Valve Academic Research Consortium-2 goes beyond the
early and intermediate experience of TAVI, drawing upon
prior surgical AVR guidelines to include time-related safety
endpoints.62 Therefore, VARC-2 recommends a new com-
posite endpoint, time-related valve safety, which combines
valve dysfunction, endocarditis, and thrombotic complica-
tions of the prosthesis (Table 11).
DISCUSSION
Although the original VARC standardized endpoint def-
initions were fundamentally useful and have been widely
adopted, growing experience with TAVI studies has identi-
fied some definitions as ambiguous, of limited clinical18 The Journal of Thoracic and Cardiovascular Surgeutility, or in need of updating or extension.5,6,63,64 This
need provided the rationale for a VARC-2 document with
such improvements and additions. As was the case with
the original VARC process, it should be emphasized that
this consensus manuscript is not intended to be a guidelines
document, but rather a practical tool to facilitate and inform
clinical research in TAVI.ry c January 2013
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risk patients, and more studies are comparing TAVI with
surgical AVR. Therefore, it becomes increasingly important
to identify those patients who benefit from either treatment.
Specific risk categories have been defined to allow universal
clinical study designs and outcome comparisons.
Changes and additions that have been applied to improve
the interpretation of clinical endpoint definitions and pro-
vide further insights on TAVI-related outcomes are as fol-
lows: (i) risk stratification should be done by a dedicated
‘‘heart team’’ and include other factors (eg, frailty, porcelain
aorta) beyond the traditional risk scores, and should take into
account coexisting conditions; (ii) immediate procedural
death has been added to capture intraprocedural events
that result in immediate or consequent death; (iii) stroke as-
certainment requires the use of precise definitions, standard-
ized assessments, close collaboration with neurology
experts including the consideration of acute stroke manage-
ment, and has been recategorized as nondisabling or
disabling; (iv) detailed documentation of the etiology of
strokes and concomitant therapies is needed to provide
insights into the multi-factorial nature of acute, early, and
late strokes; (v) closure device failure is now a separate cat-
egory within vascular complications, and if unplanned per-
cutaneous or surgical intervention does not lead to adverse
outcomes, these are not considered as amajor vascular com-
plication per se; (vi) the time for AKI diagnosis has been ex-
tended from 72 h to 7 days; (vii) AKI is diagnosed according
to AKIN guidelines, which include classification by the
urine output to detect a wider range of etiologies; (viii) peri-
procedural myocardial infarction is defined by troponin or
CK-MB elevation and the troponin threshold has changed
from 103 ULN to 153 ULN based on recent data19; (ix)
assessment of conduction disturbances and arrhythmias
has been reinforced65-68; (x) new definitions for several
TAVI-related complications and valve malpositioning are
reported; (xi) echocardiography parameters of prosthetic
valve stenosis and regurgitation have been updated and
now include the assessment of the prosthesis–patient mis-
match; (xii) for the QOL assessment, VARC-2 recommends
the use of both heart failure-specific and generic measures
during the follow-up between 30 days and 5 years to fully as-
sess the impact of the procedure and the durability of clinical
benefit. These definitions can be used in studies comparing
TAVI to surgical AVR, as well as in future trials comparing
first generation to next generation TAVI devices.
The composite endpoint of device success has specifically
been criticized for being too strict with regard to valve per-
formance; for example, an AVA>1.2 cm2 seems unachiev-
able in patients with smaller body habitus.5 The current
VARC-2 definition therefore corrects for the body surface
area so that valve performance is now assessed through the
indexed EOA. It is notable that valve-in-valve procedures
for failing bioprostheses will frequently have a low deviceThe Journal of Thoracic and Csuccess, even with this modified definition.69 Considering
that stroke has emerged as an important concern, the
composite of all-cause mortality and disabling stroke
should be considered as a primary or secondary endpoint
in future trials. Two ongoing large randomized trials (PART-
NER II [NCT01314313] and SURTAVI [NCT01586910])
are already incorporating these composite endpoints.
With longer follow-up duration, it becomesmore critical to
include time-related valve safety composite endpoints. This
will eventually provide linearized rates of complications
with transcatheter valves, known as ‘‘objective performance
criteria,’’ as has been used to evaluate surgical valves.70
With this VARC-2 document, we have provided further
standardization of endpoint definitions and hope that the
adoption of these criteria will continue to increase, ulti-
mately leading to improved comparability and interpret-
ability of the study results.
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